Clinical pharmacokinetics of oral CCNU (lomustine).
The plasma pharmacokinetics of orally administered CCNU (130 mg/m2) were studied in four patients using reversed-phase high-performance liquid chromatography (HPLC) analysis. Parent CCNU was not detected in the plasma of any of the patients, probably due to complete conversion to monohydroxylated metabolites during the 'first pass' through liver and gut. However, two monohydroxylated metabolites, trans-4-hydroxy CCNU and cis-4-hydroxy CCNU, were found at high concentrations, the relative amounts being about 6:4. Peak concentrations of the metabolites were reached 2-4 h after administration and were remarkably similar for all four patients, the total being 0.8-0.9 micrograms/ml. The metabolites were also detected in a tumour biopsy. Plasma clearance half-lives of the two metabolites were similar in each patient but showed a two-fold variation between patients, from 1.3 to 2.9 h. These results suggest that the antitumour activity and systemic toxicity of CCNU when given orally are due mainly to its monohydroxylated metabolites. Finally, comparison with data obtained in vitro and in mice showed that the nitrosourea exposures in these patients were at the lower limit of those required for significant antineoplastic activity.
D000284:Administration, Oral; D000328:Adult; D001706:Biopsy; D002430:Cecal Neoplasms / Q000188:drug therapy; D002460:Cell Line; D002851:Chromatography, High Pressure Liquid; D005910:Glioma / Q000188:drug therapy; D006207:Half-Life; D006801:Humans; D007700:Kinetics; D008130:Lomustine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000097:blood*; D008297:Male; D008545:Melanoma / Q000188:drug therapy; D008875:Middle Aged
C040831:4-hydroxylomustine; D008130:Lomustine